JP2014528901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528901A5 JP2014528901A5 JP2013557862A JP2013557862A JP2014528901A5 JP 2014528901 A5 JP2014528901 A5 JP 2014528901A5 JP 2013557862 A JP2013557862 A JP 2013557862A JP 2013557862 A JP2013557862 A JP 2013557862A JP 2014528901 A5 JP2014528901 A5 JP 2014528901A5
- Authority
- JP
- Japan
- Prior art keywords
- deoxygalactonojirimycin
- gal
- administration
- replacement therapy
- enzyme replacement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 14
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 claims 14
- 229950007469 migalastat Drugs 0.000 claims 11
- 238000002641 enzyme replacement therapy Methods 0.000 claims 10
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 claims 8
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 claims 8
- 208000024720 Fabry Disease Diseases 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451798P | 2011-03-11 | 2011-03-11 | |
| US61/451,798 | 2011-03-11 | ||
| US201161578201P | 2011-12-20 | 2011-12-20 | |
| US61/578,201 | 2011-12-20 | ||
| US201261596165P | 2012-02-07 | 2012-02-07 | |
| US61/596,165 | 2012-02-07 | ||
| PCT/US2012/028260 WO2012125402A2 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017038469A Division JP2017132780A (ja) | 2011-03-11 | 2017-03-01 | ファブリー病の治療用投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014528901A JP2014528901A (ja) | 2014-10-30 |
| JP2014528901A5 true JP2014528901A5 (enExample) | 2015-04-30 |
Family
ID=46831259
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557862A Pending JP2014528901A (ja) | 2011-03-11 | 2012-03-08 | ファブリー病の治療用投薬レジメン |
| JP2017038469A Pending JP2017132780A (ja) | 2011-03-11 | 2017-03-01 | ファブリー病の治療用投薬レジメン |
| JP2019186952A Pending JP2020033360A (ja) | 2011-03-11 | 2019-10-10 | ファブリー病の治療用投薬レジメン |
| JP2021018456A Withdrawn JP2021098697A (ja) | 2011-03-11 | 2021-02-08 | ファブリー病の治療用投薬レジメン |
| JP2023045001A Pending JP2023093448A (ja) | 2011-03-11 | 2023-03-22 | ファブリー病の治療用投薬レジメン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017038469A Pending JP2017132780A (ja) | 2011-03-11 | 2017-03-01 | ファブリー病の治療用投薬レジメン |
| JP2019186952A Pending JP2020033360A (ja) | 2011-03-11 | 2019-10-10 | ファブリー病の治療用投薬レジメン |
| JP2021018456A Withdrawn JP2021098697A (ja) | 2011-03-11 | 2021-02-08 | ファブリー病の治療用投薬レジメン |
| JP2023045001A Pending JP2023093448A (ja) | 2011-03-11 | 2023-03-22 | ファブリー病の治療用投薬レジメン |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20140219986A1 (enExample) |
| EP (2) | EP2683382B1 (enExample) |
| JP (5) | JP2014528901A (enExample) |
| KR (1) | KR20140011367A (enExample) |
| CN (2) | CN107088225A (enExample) |
| AU (6) | AU2012229330B2 (enExample) |
| CA (1) | CA2829947C (enExample) |
| CL (1) | CL2013002601A1 (enExample) |
| EA (1) | EA031874B1 (enExample) |
| ES (1) | ES2807502T3 (enExample) |
| HK (1) | HK1242998A1 (enExample) |
| MX (1) | MX2013010446A (enExample) |
| SG (2) | SG10201604757RA (enExample) |
| TW (3) | TW201740945A (enExample) |
| WO (1) | WO2012125402A2 (enExample) |
| ZA (1) | ZA201306735B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| US10077458B2 (en) * | 2014-02-17 | 2018-09-18 | Glaxosmithkline Intellectual Property Development Limited | Microbiological process |
| AU2015231307B2 (en) | 2014-03-19 | 2021-01-28 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| US10874355B2 (en) | 2014-04-24 | 2020-12-29 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
| GB201508025D0 (en) * | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| KR20190087673A (ko) * | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| CN109661230A (zh) * | 2016-07-19 | 2019-04-19 | 阿米库斯治疗学公司 | 治疗ert初治的和已经历ert的患者中的法布里病 |
| EP3539033B1 (en) | 2016-11-14 | 2024-10-02 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| CA3224546A1 (en) | 2017-05-30 | 2018-12-06 | Jeff Castelli | Use of migalastat in the treatment of fabry patients having renal impairment |
| SI3630114T1 (sl) * | 2017-05-30 | 2024-03-29 | Amicus Therapeutics, Inc. | Migalastat za zdravljenje bolnikov s fabryevo boleznijo, z ledvično okvaro |
| JP7066157B2 (ja) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| DK3840753T3 (da) * | 2018-08-20 | 2024-10-28 | Amicus Therapeutics Inc | Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet |
| KR102643554B1 (ko) | 2019-03-22 | 2024-03-04 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| AR120055A1 (es) * | 2019-06-11 | 2022-02-02 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
| US11833164B2 (en) | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| US20240197706A1 (en) * | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551177A (en) * | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| SI1589993T1 (sl) * | 2003-01-31 | 2015-05-29 | Mount Sinai School Of Medicine Of New York University | Kombinirana terapija za zdravljenje motenj pomanjkanja proteina |
| US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| CN100457106C (zh) * | 2005-06-15 | 2009-02-04 | 同济大学 | 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用 |
| PL2533050T6 (pl) * | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| EP2185187A1 (en) * | 2007-08-29 | 2010-05-19 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of alpha-galatosidase a |
-
2012
- 2012-03-08 SG SG10201604757RA patent/SG10201604757RA/en unknown
- 2012-03-08 AU AU2012229330A patent/AU2012229330B2/en active Active
- 2012-03-08 SG SG2013067954A patent/SG193379A1/en unknown
- 2012-03-08 ES ES12758017T patent/ES2807502T3/es active Active
- 2012-03-08 WO PCT/US2012/028260 patent/WO2012125402A2/en not_active Ceased
- 2012-03-08 JP JP2013557862A patent/JP2014528901A/ja active Pending
- 2012-03-08 KR KR1020137026394A patent/KR20140011367A/ko not_active Ceased
- 2012-03-08 CN CN201611235913.7A patent/CN107088225A/zh active Pending
- 2012-03-08 EP EP12758017.3A patent/EP2683382B1/en active Active
- 2012-03-08 MX MX2013010446A patent/MX2013010446A/es unknown
- 2012-03-08 CA CA2829947A patent/CA2829947C/en active Active
- 2012-03-08 US US14/004,335 patent/US20140219986A1/en not_active Abandoned
- 2012-03-08 EP EP20160164.8A patent/EP3698792A1/en active Pending
- 2012-03-08 CN CN201280021877.8A patent/CN103974619B/zh active Active
- 2012-03-08 EA EA201301018A patent/EA031874B1/ru not_active IP Right Cessation
- 2012-03-12 TW TW106126844A patent/TW201740945A/zh unknown
- 2012-03-12 TW TW105118425A patent/TWI624259B/zh not_active IP Right Cessation
- 2012-03-12 TW TW101108345A patent/TWI624258B/zh not_active IP Right Cessation
-
2013
- 2013-09-09 ZA ZA2013/06735A patent/ZA201306735B/en unknown
- 2013-09-10 CL CL2013002601A patent/CL2013002601A1/es unknown
-
2016
- 2016-06-28 AU AU2016204445A patent/AU2016204445B2/en active Active
-
2017
- 2017-03-01 JP JP2017038469A patent/JP2017132780A/ja active Pending
- 2017-10-12 US US15/782,431 patent/US20180153999A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102615.1A patent/HK1242998A1/zh unknown
- 2018-03-07 AU AU2018201637A patent/AU2018201637A1/en not_active Abandoned
-
2019
- 2019-10-10 JP JP2019186952A patent/JP2020033360A/ja active Pending
-
2020
- 2020-03-02 US US16/806,404 patent/US20200268890A1/en not_active Abandoned
- 2020-03-09 AU AU2020201715A patent/AU2020201715A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018456A patent/JP2021098697A/ja not_active Withdrawn
-
2022
- 2022-05-05 AU AU2022203011A patent/AU2022203011A1/en not_active Abandoned
-
2023
- 2023-03-22 JP JP2023045001A patent/JP2023093448A/ja active Pending
- 2023-07-17 US US18/222,745 patent/US20240115708A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205251A patent/AU2024205251A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528901A5 (enExample) | ||
| JP2020033360A5 (enExample) | ||
| JP2015519329A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP2013509411A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013541583A5 (enExample) | ||
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| JP2015522077A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RU2017105837A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией, с применением цис-кломифена | |
| JP2015512948A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| JP2015524460A5 (enExample) | ||
| RU2012122649A (ru) | Способ диагностики ишемии миокарда у больных кардиальным синдромом х |